GPCR PAR1 or DRD2-Specific Monoclonal Antibodies Can Detect the Target Expressed on Live Cell Surfaces by Flow Cytometry
Poster Abstract
Antibody staining of G protein-coupled receptors (GPCRs) on live cells is important for studying receptor expression, localization, and dynamics in their native, functional state. This approach provides a more accurate view of receptor behavior than methods that use fixed cells, which can cause artifacts and alter the receptor’s conformation. Due to their complex membrane environment, low native expression levels, and dynamic conformations, GPCRs can be difficult targets for antibodies. We have developed proprietary fit-for-target immunization approaches to generate GPCR-specific antibodies in mice. The immune mouse B cells are used for monoclonal antibody discovery for target staining on live cell surface by flow cytometry. Protease-activated receptor-1 (PAR1) and Dopamine receptor D2 (DRD2) are Class A GPCRs. PAR1- or DRD2-specific monoclonal antibodies (mAbs) were generated from immunized mice. The mAbs could stain PAR1 or DRD2 expressed on live cell surfaces by flow cytometry. As antibody staining of live GPCRs is a foundational and indispensable technique, these mAbs can be useful tools for PAR1 and DRD2 research and drug discovery.
Fit-for-Target GPCR immunogen design
Conclusions
- Rational GPCR immunogen design and proprietary immunization platforms can generate potent antibody responses in mice against GPCR protein target on live cell surface.
- PAR1-specific monoclonal antibody can specifically detect PAR1 target protein expression on live cells by flow cytometry.
- DRD2-specific monoclonal antibody can specifically detect DRD2 target protein expression on live cells by flow cytometry.
- The PAR1 and DRD2 specific mAbs can be useful tools for research and drug discovery.
Proprietary Immunization Platform to Break Immune Tolerance and Raise Antibodies Against Challenging Targets
Challenging targets include:
- Low Immunogenicity
- Extracellular Loop
- Conformational Epitopes
Learn more about Conigen’s Precision Antibody Discovery Platform



